Amarin Corp Plc (AMRN)

$0.8786

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Amarin Corp Plc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 66.05M → 75.36M (in $), with an average increase of 12.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -19.31M → -5.83M (in $), with an average increase of 231.2% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 93.8% return, outperforming this stock by 124.8%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 295.1% return, outperforming this stock by 377.9%

Performance

  • $0.87
    $0.89
    $0.88
    downward going graph

    1.65%

    Downside

    Day's Volatility :2.69%

    Upside

    1.06%

    downward going graph
  • $0.65
    $1.49
    $0.88
    downward going graph

    26.02%

    Downside

    52 Weeks Volatility :56.31%

    Upside

    40.94%

    downward going graph

Returns

PeriodAmarin Corp PlcSector (Health Care)Index (Russel 2000)
3 Months
-29.9%
2.0%
0.0%
6 Months
23.71%
11.7%
0.0%
1 Year
-30.99%
5.8%
1.3%
3 Years
-82.95%
14.2%
-22.1%

Highlights

Market Capitalization
344.9M
Book Value
$1.35
Earnings Per Share (EPS)
-0.15
PEG Ratio
-1.74
Wall Street Target Price
1.08
Profit Margin
-19.26%
Operating Margin TTM
-6.17%
Return On Assets TTM
-1.27%
Return On Equity TTM
-10.3%
Revenue TTM
306.9M
Revenue Per Share TTM
0.75
Quarterly Revenue Growth YOY
-17.2%
Gross Profit TTM
260.6M
EBITDA
-14.4M
Diluted Eps TTM
-0.15
Quarterly Earnings Growth YOY
-0.94
EPS Estimate Current Year
-0.14
EPS Estimate Next Year
-0.13
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.03

Analyst Recommendation

Hold
    10%Buy
    50%Hold
    40%Sell
Based on 10 Wall street analysts offering stock ratings for Amarin Corp Plc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
7
7
Hold
5
3
3
Sell
4
1
1

Analyst Forecast

What analysts predicted

Upside of 22.92%

Current $0.88
Target $1.08

Company Financials

FY18Y/Y Change
Revenue
229.2M
↑ 26.56%
Net Income
-116.4M
↑ 71.58%
Net Profit Margin
-50.8%
↓ 13.33%
FY19Y/Y Change
Revenue
429.8M
↑ 87.49%
Net Income
-22.6M
↓ 80.55%
Net Profit Margin
-5.27%
↑ 45.53%
FY20Y/Y Change
Revenue
614.1M
↑ 42.89%
Net Income
-18.0M
↓ 20.51%
Net Profit Margin
-2.93%
↑ 2.34%
FY21Y/Y Change
Revenue
583.2M
↓ 5.03%
Net Income
7.7M
↓ 142.94%
Net Profit Margin
1.33%
↑ 4.26%
FY22Y/Y Change
Revenue
369.2M
↓ 36.69%
Net Income
-105.8M
↓ 1468.91%
Net Profit Margin
-28.66%
↓ 29.99%
FY23Y/Y Change
Revenue
308.1M
↓ 16.55%
Net Income
-59.3M
↓ 43.91%
Net Profit Margin
-19.26%
↑ 9.4%
Q3 FY22Q/Q Change
Revenue
89.9M
↓ 4.83%
Net Income
-5.1M
↓ 92.65%
Net Profit Margin
-5.72%
↑ 68.35%
Q4 FY22Q/Q Change
Revenue
90.2M
↑ 0.41%
Net Income
856.0K
↓ 116.65%
Net Profit Margin
0.95%
↑ 6.67%
Q1 FY23Q/Q Change
Revenue
86.0M
↓ 4.73%
Net Income
-16.5M
↓ 2022.9%
Net Profit Margin
-19.15%
↓ 20.1%
Q2 FY23Q/Q Change
Revenue
80.2M
↓ 6.76%
Net Income
-17.6M
↑ 6.68%
Net Profit Margin
-21.9%
↓ 2.75%
Q3 FY23Q/Q Change
Revenue
66.1M
↓ 17.6%
Net Income
-19.3M
↑ 9.97%
Net Profit Margin
-29.23%
↓ 7.33%
Q4 FY23Q/Q Change
Revenue
75.4M
↑ 14.09%
Net Income
-5.8M
↓ 69.8%
Net Profit Margin
-7.74%
↑ 21.49%
FY18Y/Y Change
Total Assets
385.7M
↑ 138.69%
Total Liabilities
233.4M
↑ 2.95%
FY19Y/Y Change
Total Assets
882.2M
↑ 128.72%
Total Liabilities
273.9M
↑ 17.38%
FY20Y/Y Change
Total Assets
966.0M
↑ 9.5%
Total Liabilities
338.5M
↑ 23.57%
FY21Y/Y Change
Total Assets
1.1B
↑ 10.56%
Total Liabilities
401.0M
↑ 18.45%
FY22Y/Y Change
Total Assets
886.2M
↓ 17.03%
Total Liabilities
290.8M
↓ 27.46%
FY23Y/Y Change
Total Assets
831.7M
↓ 6.15%
Total Liabilities
279.6M
↓ 3.87%
Q3 FY22Q/Q Change
Total Assets
908.3M
↓ 6.67%
Total Liabilities
320.5M
↓ 18.49%
Q4 FY22Q/Q Change
Total Assets
886.2M
↓ 2.44%
Total Liabilities
290.8M
↓ 9.25%
Q1 FY23Q/Q Change
Total Assets
860.2M
↓ 2.93%
Total Liabilities
275.4M
↓ 5.31%
Q2 FY23Q/Q Change
Total Assets
860.0M
↓ 0.02%
Total Liabilities
290.9M
↑ 5.63%
Q3 FY23Q/Q Change
Total Assets
839.0M
↓ 2.44%
Total Liabilities
285.9M
↓ 1.72%
Q4 FY23Q/Q Change
Total Assets
831.7M
↓ 0.88%
Total Liabilities
279.6M
↓ 2.2%
FY18Y/Y Change
Operating Cash Flow
-94.7M
↑ 188.4%
Investing Cash Flow
-58.0K
↑ 383.33%
Financing Cash Flow
271.3M
↑ 3193.88%
FY19Y/Y Change
Operating Cash Flow
-9.4M
↓ 90.11%
Investing Cash Flow
-2.5M
↑ 4172.41%
Financing Cash Flow
409.6M
↑ 51.01%
FY20Y/Y Change
Operating Cash Flow
-21.7M
↑ 132.18%
Investing Cash Flow
-377.0M
↑ 15112.39%
Financing Cash Flow
-58.9M
↓ 114.38%
FY21Y/Y Change
Operating Cash Flow
-66.5M
↑ 205.97%
Investing Cash Flow
104.1M
↓ 127.62%
Financing Cash Flow
-5.1M
↓ 91.39%
FY22Y/Y Change
Operating Cash Flow
-180.1M
↑ 170.66%
Investing Cash Flow
175.3M
↑ 68.38%
Financing Cash Flow
-379.0K
↓ 92.53%
Q3 FY22Q/Q Change
Operating Cash Flow
-18.2M
↓ 71.8%
Investing Cash Flow
30.9M
↓ 57.82%
Financing Cash Flow
-156.0K
↓ 163.93%
Q4 FY22Q/Q Change
Operating Cash Flow
1.6M
↓ 108.52%
Investing Cash Flow
-27.8M
↓ 190.12%
Financing Cash Flow
38.0K
↓ 124.36%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.0M
↓ 551.55%
Investing Cash Flow
-19.6M
↓ 29.51%
Financing Cash Flow
364.0K
↑ 857.89%

Technicals Summary

Sell

Neutral

Buy

Amarin Corp Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amarin Corp Plc
Amarin Corp Plc
4.67%
23.71%
-30.99%
-82.95%
-95.38%
Eli Lilly And Company
Eli Lilly And Company
-3.55%
27.15%
93.77%
298.3%
530.71%
Johnson & Johnson
Johnson & Johnson
-4.31%
-1.33%
-10.08%
-8.87%
6.36%
Merck & Co. Inc.
Merck & Co. Inc.
1.25%
23.15%
9.44%
63.65%
69.78%
Abbvie Inc
Abbvie Inc
-5.04%
16.71%
2.81%
52.2%
113.69%
Pfizer Inc.
Pfizer Inc.
-4.05%
-13.51%
-34.05%
-31.95%
-33.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amarin Corp Plc
Amarin Corp Plc
NA
NA
-1.74
-0.14
-0.1
-0.01
NA
1.35
Eli Lilly And Company
Eli Lilly And Company
126.53
126.53
1.43
12.51
0.48
0.12
0.01
11.98
Johnson & Johnson
Johnson & Johnson
20.07
20.07
0.89
10.66
0.18
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
906.71
906.71
0.1
8.56
0.01
0.03
0.02
14.85
Abbvie Inc
Abbvie Inc
61.72
61.72
0.45
11.09
0.35
0.08
0.04
5.87
Pfizer Inc.
Pfizer Inc.
70.97
70.97
0.26
2.21
0.02
0.02
0.06
15.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amarin Corp Plc
Amarin Corp Plc
Hold
$344.9M
-95.38%
NA
-19.26%
Eli Lilly And Company
Eli Lilly And Company
Buy
$695.3B
530.71%
126.53
15.36%
Johnson & Johnson
Johnson & Johnson
Hold
$359.3B
6.36%
20.07
47.37%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$321.5B
69.78%
906.71
0.61%
Abbvie Inc
Abbvie Inc
Buy
$297.3B
113.69%
61.72
8.95%
Pfizer Inc.
Pfizer Inc.
Buy
$148.7B
-33.15%
70.97
3.62%

Institutional Holdings

  • Kynam Capital Management, LP

    3.00%

  • Sarissa Capital Management LP

    2.60%

  • Eversept Partners, LLC

    1.52%

  • TANG CAPITAL MANAGEMENT LLC

    1.46%

  • Morgan Stanley - Brokerage Accounts

    1.39%

  • DG Capital Management, LLC

    1.35%

Corporate Announcements

  • Amarin Corp Plc Earnings

    Amarin Corp Plc’s price-to-earnings ratio stands at None

    Read More

Company Information

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.

Organization
Amarin Corp Plc
Employees
275
CEO
Mr. Patrick J. Holt
Industry
Health Technology

Discover More

FAQs